Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-02-02 00:00:00 ET · period of report 2023-01-31 · accession 0001209191-23-006215 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-02 | 2023-01-31 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $325.00 | -106 | 38.0K | -0.3% | -$34.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-31 | S | D | 106 | $325.00 | 37,998 | D | — | — |